LUCD Key Statistics, Chart & Performance
The current stock price of LUCD is 1.08 USD. In the past month the price increased by 3.96%. In the past year, price increased by 28.05%.
LUCD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.19 | 218.56B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.31 | 202.39B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.46 | 141.94B | ||
| SYK | STRYKER CORP | 26.8 | 135.00B | ||
| BDX | BECTON DICKINSON AND CO | 13.55 | 55.77B | ||
| IDXX | IDEXX LABORATORIES INC | 53.95 | 54.32B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.42 | 49.84B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.02 | 37.67B | ||
| RMD | RESMED INC | 24.5 | 35.41B | ||
| DXCM | DEXCOM INC | 35.88 | 26.03B | ||
| PODD | INSULET CORP | 62.54 | 20.11B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.18 | 17.93B |
Related stock screener links
About LUCD
Company Profile
Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. The company is headquartered in New York City, New York and currently employs 72 full-time employees. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The company is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.
Company Info
LUCID DIAGNOSTICS INC
360 Madison Avenue, 25th Floor
New York City NEW YORK US
Employees: 72
Phone: 12129494319
LUCID DIAGNOSTICS INC / LUCD FAQ
What does LUCD do?
Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. The company is headquartered in New York City, New York and currently employs 72 full-time employees. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The company is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.
What is the stock price of LUCID DIAGNOSTICS INC today?
The current stock price of LUCD is 1.08 USD. The price increased by 2.86% in the last trading session.
Does LUCD stock pay dividends?
LUCD does not pay a dividend.
What is the ChartMill technical and fundamental rating of LUCD stock?
LUCD has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists LUCD stock?
LUCD stock is listed on the Nasdaq exchange.
Can you provide the growth outlook for LUCID DIAGNOSTICS INC?
The Revenue of LUCID DIAGNOSTICS INC (LUCD) is expected to grow by 3.8% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for LUCID DIAGNOSTICS INC?
LUCID DIAGNOSTICS INC (LUCD) has a market capitalization of 141.39M USD. This makes LUCD a Micro Cap stock.
LUCD Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to LUCD. When comparing the yearly performance of all stocks, LUCD is one of the better performing stocks in the market, outperforming 80.15% of all stocks.
LUCD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LUCD. LUCD has a bad profitability rating. Also its financial health evaluation is rather negative.
LUCD Financial Highlights
Over the last trailing twelve months LUCD reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS increased by 22.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -123.77% | ||
| ROE | -254.86% | ||
| Debt/Equity | 0.86 |
LUCD Forecast & Estimates
12 analysts have analysed LUCD and the average price target is 3.87 USD. This implies a price increase of 258.1% is expected in the next year compared to the current price of 1.08.
For the next year, analysts expect an EPS growth of 33.6% and a revenue growth 3.8% for LUCD